Search results
Results from the WOW.Com Content Network
Overall, the five-year survival rate for triple-negative breast cancer is 77% compared to the five-year survival rate of 91% for breast cancer in general. Triple-negative breast cancer is also more likely to recur (come back) after treatment.
Survival rates for triple-negative breast cancer TNBC tends to grow quickly, is more likely to have spread at the time it’s found, and is more likely to come back after treatment than other types of breast cancer.
TNBC accounts for approximately 10–15% of all breast cancers. This article reviews survival rates for people with TNBC, and the factors that affect those survival rates. What are the survival...
What is the survival rate for triple-negative breast cancer? The survival rate for TNBC depends on several factors, including: if the cancer has spread, how well the tumor responds to treatment and; the patient's overall health.
A new multicenter, international study suggests that people who have early-stage triple-negative breast cancer (TNBC) and high levels of immune cells within their tumors may have a lower risk of recurrence and better survival rates even when not treated with chemotherapy.
Triple-negative breast cancer is an aggressive, fast-growing form of breast cancer. The 5-year relative survival rate for this cancer is 77%. Read more here.
What are survival rates for triple-negative breast cancer? According to the American Cancer Society, survival rates vary depending on cancer stage at diagnosis: Local or Stage 0–Stage 1 survival rate: More than 90% of people were alive five years after diagnosis.
Triple-negative breast cancer can spread faster and is more likely to recur than other types of breast cancer. With early diagnosis, the 5-year survival rate is 91%, but rates are lower for...
Triple-negative breast cancer (TNBC) is an aggressive cancer, meaning it grows and spreads quickly. It’s more likely than other breast cancers to return, and it has more limited treatment options, which tends to make for a poorer prognosis.
Metastatic triple-negative breast cancer is an aggressive cancer with an average survival of 8 to 13 months. However, survival varies significantly among patients. We studied a large group of women in the National Cancer Database to better understand these survival differences.